1. Home
  2. BNGO vs INTS Comparison

BNGO vs INTS Comparison

Compare BNGO & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bionano Genomics Inc.

BNGO

Bionano Genomics Inc.

HOLD

Current Price

$1.20

Market Cap

12.9M

Sector

Industrials

ML Signal

HOLD

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

HOLD

Current Price

$4.78

Market Cap

12.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNGO
INTS
Founded
2003
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.9M
12.9M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
BNGO
INTS
Price
$1.20
$4.78
Analyst Decision
Strong Buy
Buy
Analyst Count
2
3
Target Price
$7.00
$38.00
AVG Volume (30 Days)
127.0K
64.3K
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
94.50
N/A
EPS
N/A
N/A
Revenue
$12,000,735.00
N/A
Revenue This Year
$14.99
N/A
Revenue Next Year
$34.73
N/A
P/E Ratio
N/A
N/A
Revenue Growth
26.26
N/A
52 Week Low
$1.06
$0.19
52 Week High
$5.50
$8.06

Technical Indicators

Market Signals
Indicator
BNGO
INTS
Relative Strength Index (RSI) 54.67 66.87
Support Level $1.13 $4.50
Resistance Level $1.31 $8.06
Average True Range (ATR) 0.04 0.23
MACD 0.00 0.13
Stochastic Oscillator 91.62 83.34

Price Performance

Historical Comparison
BNGO
INTS

About BNGO Bionano Genomics Inc.

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.

Share on Social Networks: